IQVIA (IQV) to Release Quarterly Earnings on Tuesday

IQVIA (NYSE:IQV) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, July 22nd. Analysts expect IQVIA to post earnings of $2.76 per share and revenue of $3.96 billion for the quarter. IQVIA has set its FY 2025 guidance at 11.700-12.100 EPS.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.54 EPS. On average, analysts expect IQVIA to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Performance

IQV stock opened at $160.06 on Tuesday. The stock’s 50 day simple moving average is $152.11 and its 200 day simple moving average is $171.51. The stock has a market capitalization of $27.69 billion, a PE ratio of 21.81, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. IQVIA has a 12-month low of $134.65 and a 12-month high of $252.88.

Institutional Trading of IQVIA

An institutional investor recently raised its position in IQVIA stock. Empowered Funds LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 102.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,728 shares of the medical research company’s stock after buying an additional 4,915 shares during the period. Empowered Funds LLC’s holdings in IQVIA were worth $1,715,000 as of its most recent SEC filing. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Hsbc Global Res cut IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Barclays decreased their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 7th. Mizuho cut their price target on IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a research note on Thursday, May 15th. Citigroup reiterated a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Evercore ISI raised their price objective on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, July 9th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $222.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.